TruthArchive.ai - Related Video Feed

The discussion centers on concerns and policy questions regarding pediatric vaccines, their safety, and how authorities respond to families who choose not to vaccinate. Key points raised by Speaker 0: - Pediatric vaccination schedules are increasing, with currently up to about 30 doses from birth to 2 years. Some vaccines, such as the hepatitis B vaccine, the acellular pertussis (3-in-1) vaccine, and the influenza vaccine given after 6 months, contain additives such as thiomersal (mercury-containing compound) and aluminum adjuvants. There is worry among some about potential long-term effects on brain development from thiomersal and other additives. - Thiomersal in vaccines is described as an organomercury compound that decomposes to ethyl mercury; historical notes are given about its association, in some sources, with developmental disorders in the 1990s, and there is reference to materials from the Ministry of Health, Labour and Welfare explaining its presence in certain vaccines and associated documentation. - The vaccine components discussed include thiomersal in current hepatitis B vaccines (e.g., Belcevir or Veemegen trade names), and aluminum-containing compounds in combination vaccines and the cervical cancer vaccine (HPV). There are concerns about neurotoxicity and memory impairment reported in some sources, and questions are raised about how these substances are evaluated in light of pediatric metabolism and excretion. - The text also points to broader concerns about modern additives in foods (artificial sweeteners, neonicotinoids, tar dyes) as part of a context for questioning vaccine safety, though the central focus remains vaccines and their additives. Speaker 0 also emphasizes a paradox: despite declining birth rates, the number of children with developmental disorders such as ADHD, autism spectrum disorders, and learning disabilities has risen, leading to heightened parental anxiety about early vaccination (birth to 2 months). The speaker highlights that even if experts claim the amounts are tiny, parents’ concerns persist. A call is made to present attached documentation and graphs to explain these points, as well as the overall safety profile. Questions and responses about policy and practice: - Speaker 1 explains preventive vaccination law (Article 8 and 9) authorizing municipalities to issue guidance and reminder notices for vaccinations, including vaccines against measles, rubella (MR), HPV, and Japanese encephalitis (the latter appears in the discussion as often related to catch-up schedules). The notices are for encouragement, not coercive mandates. - On the issue of refusals and potential neglect: it is stated that vaccinating of unvaccinated children is not, by itself, considered neglect; the decision to not vaccinate does not automatically constitute abuse or neglect. The speaker emphasizes that the question is about ensuring access to vaccination information and avoiding punitive labeling. - The role of childcare facilities and schools: there is discussion about whether vaccination status affects eligibility or admission. It is clarified that vaccination history is part of health records but does not automatically disadvantage a child in admission processes. Authorities acknowledge that some educators may view non-vaccination as neglect, and there is a preference to improve information sharing and awareness so that staff understand vaccination matters without stigmatizing families. - The need for uniform understanding among healthcare workers and educators is stressed. It is suggested that vaccination-related information be shared between childcare, school administration, and health departments to minimize misunderstandings and to ensure equitable treatment. - There is acknowledgement of concerns about social attitudes toward families who opt out of vaccination, and a call to respect differing judgments while improving communication and education among professionals. Speaker 3 and 4 contribute: - They reiterate that in childcare settings, health screening and eligibility processes may consider vaccination history, but not in a way that inherently disfavors unvaccinated children. They also address the possibility of attitudes among staff about neglect, noting a need for consistent information, training, and collaboration to reduce stigma. - A broader aim is expressed: foster a society where mutual respect for different vaccination decisions is possible, supported by clear communication and shared information among healthcare providers and educators. Overall, the discussion distinguishes between official guidance and punitive actions, reinforces that unvaccinated status alone is not treated as neglect, and calls for better information-sharing and supportive responses to families navigating vaccination decisions.

Kevin McKernan provides a whirlwind tour of DNA contamination in vaccines. He highlights the existence of DNA contamination in vaccines based on various studies and documents. McKernan criticizes the regulators' response, stating that they have turned to the vaccine manufacturers for answers, which he believes are misleading. He also discusses the use of different measurement methods and the potential risks associated with DNA contamination, including the integration of foreign DNA into human cells. McKernan calls for further screening of various biological samples for vaccine residue and encourages CLIA Laboratories to take an interest in this matter.

The speakers discuss the presence of various substances in childhood vaccines. They mention that some vaccines contain monkey kidney cells, bovine serum, guinea pig cell cultures, cow's milk, egg protein, gelatin from pigs, and human albumin. They also mention the use of MRC5 and WI38 human diploid cells in vaccine production. The speakers touch on the fragmentation of human DNA in vaccines and the safety studies conducted. They discuss a study involving the harvesting of tissues from aborted fetuses for vaccine development. The inclusion of fetal tissue in vaccines is mentioned as an objection by some individuals. The conversation concludes with a mention of a pig virus found in a rotavirus vaccine and a discussion on religious objections to vaccines.

The speaker discusses the Vaxelis vaccine, a six-in-one vaccine for children aged six weeks to four years, protecting against diphtheria, tetanus, pertussis, polio, Haemophilus B, and hepatitis B. The speaker references the package insert, noting epinephrine and other agents should be available during administration. The speaker highlights a review by the Institute of Medicine that found a causal relationship between tetanus toxoid and both brachial neuritis and Guillain Barre syndrome, a type of paralysis. Apnea following intramuscular vaccination has been observed in some infants. The speaker claims there were no randomized controlled studies with an inert placebo during the vaccine's development, only tests against other vaccinations. Ingredients include aluminum, formaldehyde, bovine serum albumin, neomycin, Streptomycin, and Polymyxin B. The speaker points out that Vaxelis has not been evaluated for carcinogenic or mutagenic potential or impairment of fertility.

The speaker believes all vaccines are suspect. As an emergency medicine physician, the speaker thought vaccines only contained a dead or attenuated virus and saline. In September 2000, after reading a package insert and researching vaccines, the speaker was mortified to learn that a child receiving all scheduled vaccines gets almost 13,000 micrograms of aluminum, almost 600 micrograms of mercury, and over 200 chemicals. The speaker states that this is why vaccines have never been proven safe, and vaccination is like injecting foreign matter into a baby.

Flu vaccines are administered annually starting at six months old, with nine branded options available in the U.S. A CDC document lists all vaccine ingredients, revealing that three flu vaccines contain hydrocortisone, a corticosteroid known to suppress the immune system. This raises questions about the effectiveness of flu vaccines, which are marketed to boost immunity. Additionally, one vaccine contains Madine Darby canine kidney cells, which are highly susceptible to the flu virus. Other concerning ingredients include formaldehyde and polysorbate 80, which can affect the blood-brain barrier. The hepatitis B vaccine also contains MRC-5 cells derived from a fetus, prompting further scrutiny about the ingredients in vaccines and their implications for health.

The speaker discusses the American Academy of Pediatrics' recommendation to ban all vaccine exemptions, noting that 50% of pediatricians' revenue comes from well-child check vaccine schedules. The speaker focuses on the Vaxelis vaccine by Merck, a six-in-one vaccine for children aged six weeks to four years, containing diphtheria, tetanus, pertussis, polio, haemophilus B, and hepatitis B. The speaker highlights that the Institutes of Medicine found a causal relationship between Vaxelis and Guillain Barre syndrome. Each dose contains 319 micrograms of aluminum, formaldehyde, bovine serum albumin, and antibiotics like neomycin, streptomycin, and polymyxin B. The speaker points out that Vaxelis has not been evaluated for carcinogenic or mutagenic potential or impairment of fertility.

A speaker is sharing information about the Vaxelis vaccine, referencing the package insert. The vaccine is a six-in-one shot for diphtheria, tetanus, pertussis, polio, haemophilus b, and hepatitis b, indicated for children six weeks to four years old. The speaker notes epinephrine and other equipment must be available during vaccination. The Institute of Medicine found a causal relationship between tetanus toxoid and brachial neuritis and Guillain Barre syndrome. Apnea has been observed in some infants after intramuscular vaccination. The speaker claims there were no randomized controlled studies with an inert placebo, only tests against other vaccines. Ingredients include 319 micrograms of aluminum, formaldehyde, bovine serum albumin, neomycin, streptomycin, and polymyxin b. The speaker points out that Vaxelis has not been evaluated for carcinogenic or mutagenic potential or impairment of fertility.

According to the speaker, most vaccines have never been tested in a randomized, placebo-controlled trial to evaluate their safety. The speaker claims that vaccines contain aluminum compounds because many dead vaccines don't mount an immune response without them. The speaker alleges that in a Gardasil vaccine study, the placebo group received an aluminum adjuvant instead of a true placebo, resulting in similar side effect profiles between the active vaccine and placebo groups. The speaker asserts that Merck used a novel aluminum compound and that data suggests aluminum in vaccines is profoundly toxic. The speaker states that the only true randomized controlled trial involving a vaccine was conducted on sheep with blue tongue disease. The results allegedly showed that the aluminum in the vaccine was toxic, causing the sheep to become sick, unsociable, and, in some cases, die. The speaker concludes that the assumption that aluminum adjuvants in vaccines are safe is unfounded and has never been tested.

This is a discussion about the Gardasil cervical cancer vaccine and a core issue believed to be at the heart of global legal actions, with a focus on contaminant DNA linked to the aluminum adjuvant and the evidence that emerged from studies conducted at that time. Speaker 0 explains that the vaccine, including Gardasil, has become the subject of surprising court cases worldwide, with large plaintiff groups in Japan composed largely of young women and girls. The central issue, according to the speaker, is the contamination of the D-N-E (DNA) in the vaccine, which has been the topic of concern since the early days, with the Ministry of Health, Labour and Welfare in Japan reportedly recognizing this as the core problem. In 2012, a paper made the DNA contamination issue very clear, showing that the HPV DNA fragments for HPV types 16, 18, 6, and others associated with the vaccine were found in the vaccine samples. The speaker notes that the Hepatitis B, HPV, and ERV (endogenous retrovirus) elements were involved in the analysis and that it was proposed that the DNA could bind to the aluminum adjuvant particles within the vaccine. The speaker mentions Shin Handei (Shin Han-ji) as an early voice raising alarms about the DNA contamination problem during the pandemic period, and that Kevin-sensei (Professor Kevin) referenced this work about a month earlier. The discussion highlights that doctors worldwide, listening to the voices of women and girls, observed that the same concerns about unusual adverse events after vaccination emerged globally. The claim is that residual HPV DNA from Gardasil was present in multiple samples and that the DNA, when tested, appeared to be identical in sequence to the described HPV DNA. The speaker states that eighteen types of samples were examined from countries including Australia, Bulgaria, France, India, New Zealand, Poland, Russia, Spain, and the United States. According to the account, 16 and 18 types were the primary concern, and the remaining DNA fragments were reported to be directly bound to aluminum adjuvant particles. The speaker cites that 16-part packages of Gardasil-4, when examined, contained residual HPV DNA fragments bound to aluminum adjuvant particles, and that the DNA sequences matched those identified by PCR. This was reported as having occurred in 2012. Subsequently, in 2014, the vaccine program in Japan was halted, with introduction on April 1st and cessation shortly thereafter due to the emerging concerns. In 2014, Shin Handi, Jerôme from France, and Dalma from the UK were noted as participants in a conference where the discussion continued, including claims that in 2014 the concern about residual HPV DNA led to stronger actions regarding testing and safety discussions. The dialogue then references broader regulatory contexts: a 2016 document indicating changing standards for DNA remnants (with WHO and FDA guidance) and the notion that DNA contamination thresholds were being adjusted—such as the threshold changing from 10 picograms to 100 times higher over the years, and later to roughly 10,000 picograms. The implication is that the fixed safety limits were evolving in a way that favored pharmaceutical manufacturers, with the argument that the changes in base values were not aligned with human biology, but rather with manufacturing practices. The speakers emphasize that in Japan, the issue of DNA contamination was broadcast worldwide, with researchers, journalists, and affected individuals all aware of the problem and the stakes involved, making Japan a central stage for these concerns. Speaker 1 adds that a year prior, it became clear that female safety and the DNA contamination issue were major questions in Japan, leading to discussions about stopping messenger-type vaccines and reconsidering RN-type vaccines, given the fatalities associated with those vaccine deployments, reinforcing opposition among certain groups. The exchange ends with a reaffirmation of concern about the continued risk and opposition.

Speaker 0 describes a highly significant and controversial issue surrounding human papillomavirus (HPV) vaccines, including Gardasil and Cervarix, and reports that lawsuits are occurring worldwide. In Japan, there have been major lawsuits with hundreds of plaintiffs, including young women and girls, though the fundamental problem, according to the speaker, centers on contamination with DNA impurities. The speaker states that from the early days of the Ministry of Health, Labour and Welfare in Japan, the core issue has been the contamination with DNA impurities in vaccines, and that this problem had already become clear by 2012 in a widely cited paper. The speaker explains that by 2012, a paper described the DNA contamination in Gardasil-related vaccines, specifically noting residual DNA fragments from HPV types 16 and 18 associated with the vaccine’s aluminum adjuvant particles. The claim is that vaccine samples contained residual HPV DNA fragments that were directly bound to aluminum adjuvant particles, and that PCR tests confirmed these DNA fragments were identical to the HPV sequences described in the paper. The speaker emphasizes that researchers around the world—doctors and researchers listening to women and girls’ voices—noticed unusual, severe post-vaccination symptoms in children and young women, and saw potential links between these symptoms and the residual HPV DNA attached to adjuvants. The testimony references samples gathered from multiple countries (Australia, Bulgaria, France, India, New Zealand, Poland, Russia, Spain, and the United States) and asserts that nearly all of the Gardasil/HPV vaccine lots examined contained residual HPV DNA attached to aluminum adjuvant particles. The speaker mentions that in the specific investigation, sixteen samples of Gardasil-4 contained residual HPV DNA fragments bound to aluminum adjuvant particles, and that all samples tested via PCR showed the same DNA sequence as described in the 2012 paper. The speaker claims that in 2014, the vaccine program for cervical cancer halted in Japan, and that the subsequent attention brought this issue to light publicly. The discussion attributes the major role to a Japanese expert, Ishii Ken (Ishii-sensei), described as a leading figure in Japan’s vaccine adverse-event research. The speaker recounts that, in the years around 2012–2014, efforts involved international collaboration with HR/HSA, FDA, and others, although logistical obstacles caused delays. The speaker notes that in 2012, 16 vaccine packages were distributed in nine countries for examination and that contamination persisted in all samples. They credit Japan with acting as a global relay for disseminating information about DNA contamination and its potential health implications. Further, the speaker references a broader context: the later emergence of literature discussing how DNA contamination might relate to adverse neurological or systemic symptoms, and the evolution of guidelines on acceptable residual DNA in vaccines. The discussion mentions that WHO and FDA guidelines permit changing permissible DNA limits over time, with higher thresholds introduced for manufacturing and regulatory purposes, raising questions about what constitutes safety and what is permissible in drug development. The dialogue closes with Speaker 1 alluding to the seriousness of the issue, noting deaths in the context of messenger-type vaccines and subsequent debates about vaccine safety, while acknowledging that those opposed to this view are also active.

The speaker discusses a recommendation from the American Academy of Pediatrics to ban all vaccine exemptions, noting that 50% of pediatricians' revenue comes from well-child check vaccine schedules. The speaker focuses on the Vaxelis vaccine by Merck, a six-in-one vaccine for children aged six weeks to four years, protecting against diphtheria, tetanus, pertussis, polio, haemophilus B, and hepatitis B. The speaker highlights that the Institutes of Medicine found evidence for a causal relationship between Vaxelis and Guillain Barre syndrome. Each dose contains 319 micrograms of aluminum, formaldehyde, bovine serum albumin, and antibiotics like neomycin, streptomycin, and polymyxin B. The speaker points out that Vaxelis has not been evaluated for carcinogenic or mutagenic potential or impairment of fertility.

The speaker discusses the Vaxelis vaccine, a six-in-one vaccine for children aged six weeks to four years, protecting against diphtheria, tetanus, pertussis, polio, Haemophilus B, and hepatitis B. The speaker notes the package insert states epinephrine and other agents must be available during vaccination. They highlight a review by the Institute of Medicine found a causal relationship between tetanus toxoid and both brachial neuritis and Guillain Barre syndrome, a type of paralysis. Apnea following intramuscular vaccination has been observed in some infants. The speaker claims there were no randomized controlled studies with an inert placebo, only tests against other vaccines. Ingredients include aluminum, formaldehyde, bovine serum albumin, neomycin, Streptomycin, and Polymyxin B. The speaker points out Vaxelis has not been evaluated for carcinogenic or mutagenic potential or impairment of fertility.

- In order to make a vaccine, so you first have to extract disease from an animal or a human. - Because you can't just inject live measles into a person. - You first have to do what they call attenuating it, which is to make it less virulent. - There's a myriad of monkey kidney cells that are still used today, they've been used for a very long time. - There have been monkey viruses that were finally, after thirty years, acknowledged to have been causing tumors in human beings, been associated, heavily associated with tumors in human beings. - In addition to that, there are various unknowns that can't be picked up during testing because if you don't know something is in a vaccine, you can't test for it. - Viruses, stray viruses have been found by third parties in vaccines.

The speakers discuss the vaccination landscape around human papillomavirus (HPV) vaccines, focusing on a controversial issue they claim has been known and disseminated since early on: contamination with DNA (DNA residuals) from Deinococcus or related genetic material in vaccines and the implications of aluminum adjuvants used in Gardasil/Gardasil 9. - They begin by asserting that HPV vaccines, including Gardasil/Sil, have been the subject of remarkable legal actions worldwide, including four major lawsuits in Japan. They note that historically, in Japan, many young women and girls stood as plaintiffs, and that the core problem they highlight is the DNA contamination issue (referred to as “ディー エ ヌ エー 混 入 汚 染 問 題”). - The claim is that from early on, the Japanese Ministry of Health, Labour and Welfare and others acknowledged this contamination as central. They reference a 2012 paper that reportedly made the DNA contamination problem very clear, naming pathogens such as Human Papillomavirus, HPV, and DEIN? They describe that vaccine particles (HBV? HPBL DNA fragments) were found to be directly bound to aluminum adjuvant particles in Gardasil, implying a mechanism by which residual DNA could be involved in adverse effects. - The speakers say that the 2012 study, and subsequent work, led to attention from doctors worldwide who listened to the voices of women and girls and wondered what was happening with the vaccine recipients. They claim that samples showed that residual HPV DNA fragments were consistently present and directly linked to aluminum adjuvant particles, and that “PCR” detection indicated the same DNA sequences across samples. They mention that the 2012 paper’s findings were followed by reporting that, by 2014, vaccination had been suspended in Japan earlier than many would have expected. - They recount a process in which major scientists from various countries (France, the UK, and others) were involved in investigating adenoviral or genetic components (they reference Shihan? and others) and that the Japan-based researchers, including Ishii Ken, were central figures. They describe meetings, PowerPoint presentations at a hotel, and a sequence of visits to the UK and the US (including HR-related planning with U.S. FDA and the UK authorities) that were interrupted by closures in the Obama era, leading to documentation and discussions about the safety concerns. - The speakers claim that by the 2012 report and again by 2014, all vaccine samples from multiple countries contained residual DNA, and that Japan became a hub for disseminating awareness of these issues globally. They state that the issue was present not only in the early Gardasil (Gardasil-4) but also in later forms, with references to Gardasil-9 and the idea that the DNA contamination and adjuvant interactions could contribute to immune and neurological symptoms in recipients, particularly in women and girls. - They discuss changes to WHO and FDA guidelines on residual DNA limits, noting a progression from 10 picograms to higher thresholds over time, implying corporate interests in allowing higher residual DNA quantities in vaccines. They emphasize that the shift in limits is tied to pharmaceutical companies’ needs, not human biology changes, and argue that Japan highlighted the problem of Deinance-DNA contamination during the cervical cancer vaccine era, signaling that researchers, journalists, and victims were aware long before others. - Finally, Speaker 1 adds that two points became clear a year earlier: the disruption of messenger RNA–type vaccines as a response to safety concerns, and the subsequent rise in adverse outcomes after widespread vaccination, including deaths, which they claim intensified opposition to these vaccines. Note: The summary presents the speakers' claims and sequencing of events as described in the transcript without evaluation or endorsement.

Vaccine ingredient lists are the most important lists parents have never read. Vaccines contain viruses and bacteria that must be cultured and grown. These cultures are grown in various animal cells, including monkey, dog, chicken, rabbit, and mouse cells. Many vaccines are grown with aborted fetal cells. Individuals should consider whether they support the use of aborted baby cells in vaccine manufacturing and their subsequent injection into babies, even if they support abortion in general.

Vaccines contain various ingredients, including viruses, ethylmercury, aluminum, phenol formaldehyde, antifreeze, foreign RNA and DNA, animal DNA, and nanotechnology. These components can pass through the blood-brain barrier. The SV 40 virus, which could be deadly, was a result of undisclosed research. The scientist who discovered it, Dr. Mary Sherman, was killed, and her work was likely confiscated. The fear of germs persists, but having a strong immune system can protect against them.

Well, the polio vaccine does. Yes, SV40. Semien virus forty. There's a pig virus present in one of the rotavirus vaccines, circovirus. Calf serum is removed before the vaccine is used because you don't want to sensitize the vaccinee to cows. Varicella vaccine was passage in guinea pig cells. Do any vaccines contain egg protein? Yes, influenza. Do any vaccines contain gelatin from pigs? Yes. Do any vaccines contain MRC5 human diploid cells? Yes. Rubella, varicella, hepatitis A. What are MRC5 cells? They are human fibroblast cell strain. They were created by taking fetal tissue and from a particular fetus that was aborted by maternal choice. WI38? Used to, but I don't think anything is made in those cells anymore. Isn't it true that human DNA in vaccines is typically purposely fragmented? Yes. This study involved 74 fetuses. The Catholic church has issued a document on that which says that individuals who need the vaccine should receive the vaccines regardless of the fact. Are you an atheist? Yes. When you were a child, what vaccines did you receive? Diphtheria, well, in childhood I think it was probably only Diphtheria.

The speakers discuss the presence of animal viruses in vaccines, such as SV 40 and circovirus. They also mention the use of animal-derived ingredients like cat serum, guinea pig cell cultures, cow's milk, egg protein, gelatin from pigs, and human albumin. The use of human cell lines, specifically MRC 5 and WI 38, in vaccine production is also mentioned. The discussion touches on the fragmentation of human DNA in vaccines and the safety studies conducted. The speakers mention a study involving the harvesting of tissues from 76 aborted fetuses for vaccine development. The objection to using aborted fetal tissue in vaccines is brought up, with one speaker expressing support for vaccination regardless of religious objections. The conversation ends with a discussion on the speaker's personal vaccination history.

There is significant DNA contamination found in vaccines, with evidence from multiple researchers in Germany, Japan, and the U.S. Regulatory bodies like the FDA and EMA acknowledge this contamination but downplay its significance, relying on Pfizer's assurances. The clinical trials used cleaner DNA, but the mass-produced vaccines did not undergo the same purification, leading to increased background DNA and endotoxin levels. Regulators received a plasmid map missing crucial annotations, suggesting manipulation. Claims about expired vials and PCR methods used to measure contamination have been challenged, with evidence showing that Moderna's vaccines are cleaner. Regulators are allowing different measurement standards for RNA and DNA, raising concerns about transparency and integrity in the regulatory process.

The panel discusses replication (replicon) vaccines and their potential dangers, focusing on how they differ from conventional messenger RNA (mRNA) vaccines and what new risks might emerge as this technology develops. Key points and concerns raised - Replicon vaccines concept and fundamental differences - Replicon vaccines use replication-capable genetic material, so the embedded genetic information not only makes antigen proteins but also multiplies inside the cell. They are described as having both constitutive function (the ability to make proteins) and, crucially, the capacity to replicate, which distinguishes them from traditional, non-replicating mRNA vaccines. - It is explained that replication introduces additional mutation and recombination opportunities, because the RNA genome is copied more than once, and the process can produce variants that differ from the original design. - Central dogma exceptions and viral biology - The speakers explain that while the central dogma (DNA → RNA → protein) generally governs biology, some viruses violate this, with RNA viruses that replicate via RNA-dependent replication and even some reverse-transcribing retroviruses that convert RNA to DNA and integrate into genomes. This context is used to frame why replicon vaccines could behave unpredictably. - Potential risks of replication and spread - A core concern is that the replicon approach might allow the vaccine genome to spread beyond the initial target cells, potentially reaching other cells and tissues, or even spreading to other people via exosomes or other means. Exosomes can transport DNA, RNA, and proteins between cells; thus, the replicon genome could in theory be disseminated. - The possibility of homologous or heterologous recombination between replicon genomes and wild-type viruses could yield new variants. The panel emphasizes the difficulty of controlling such recombination in a living system. - Specific material and design considerations - The use of viral components like spike protein genes in replicon vaccines raises concerns about how these proteins might mutate or recombine during replication, potentially altering antigen presentation or safety. - A concern is raised about the lack of repair mechanisms in RNA replication (as opposed to DNA replication), which could make error rates higher and lead to unpredictable changes. - The panel notes that current replicon vaccine designs (including those using alphavirus backbones) inherently carry high mutation and recombination risk, and that the replicating systems may encounter unpredictable evolutionary dynamics inside the human body. - Safety signals and clinical anecdotes - The speakers cite cases of adverse events temporally associated with vaccines, including vascular inflammation and thrombosis, stroke-like events, and myocarditis, to illustrate that immune responses to vaccines can be complex and occasionally severe. They emphasize that such observations do not establish causality, but argue they warrant careful scrutiny. - There are references to cases of acute vascular and neural complications following repeated vaccination, and to broader immune dysregulation phenomena, including IGG4-related disease and immune dysregulation syndromes that can involve multiple organs. - One example concerns a patient who developed sudden limb problems after the third dose, requiring surgery; another describes myocardial involvement after multiple doses and subsequent inflammatory sequelae. - DNA contamination and analytical findings - Kevin McKernan’s analysis of certain Japanese CoronaVac vaccines is cited: both DNA contamination and the presence of SV40 promoter elements were detected in some vaccine lots, with DNA amounts exceeding some regulatory benchmarks in at least one case. The concern is that DNA contamination, or the presence of promoter sequences, could influence integration or expression in unintended ways. - It is noted that vaccines using lipid nanoparticles can potentially deliver nucleic acids into cells; in the presence of exons or promoter sequences, there could be unintended cellular uptake and expression. - Implications for public health and policy - The panel underscores the need for caution, thorough investigation, and long-term observation of any replication-based vaccine platform before broad deployment. There is a call to evaluate risks, monitor long-term outcomes, and consider the possibility that replication-competent constructs could drive unforeseen evolutionary dynamics within hosts or communities. - There is contention about how information is communicated to the public, with particular emphasis on avoiding misinformation while ensuring that scientific uncertainties are transparently discussed. - Broader scientific context and forward-looking stance - The speakers discuss how the field’s approach to gene-based vaccines is evolving rapidly, and they stress that the compatibility of replicon systems with human biology is not yet fully understood. - They frame their discussion as not merely about current vaccines but about the trajectory of vaccine platforms: if replication-based or self-dispersing systems prove too risky or unpredictable, the prudent path might be to favor conventional, non-replicating strategies until safety, efficacy, and containment of unintended spread are more firmly established. Closing and takeaways - The session closes with emphasis on careful evaluation of replicon vaccines, awareness that viral genetics can behave differently in humans than in theory, and a call for continued discussion, independent verification, and transparent communication as the technology develops. - Throughout, speakers acknowledge the complexity of immune responses to vaccines, the potential for unexpected adverse events, and the importance of safeguarding public health while advancing vaccine science.

Pfizer and Moderna vaccines use two processes. The first process involves using PCR to amplify and create DNA for clinical trials. Once approved, they use circular bacterial DNA plasmid to replicate billions of mRNA DNA sample copies. However, this resulted in contaminated vaccines with junk DNA. A study found DNA fragments in Pfizer and Moderna vaccines in Ontario, Canada. Researchers tested 27 mRNA vials from 12 different lots and discovered billions to 100 billions of DNA molecules per dose, exceeding FDA and WHO guidelines by 188 to 509 times. This is a significant amount, far beyond what is acceptable.

Kevin discovered that the vials used for vaccines are contaminated with bacterial DNA. This is concerning because the modified RNA used in these vaccines creates unusual genetic structures that don't occur naturally. Normally, DNA is in a double helix form, but with modified RNA, there are three strands attached to the DNA. The enzyme used to remove DNA, called DNase, cannot digest these triple-stranded genetic constructs, resulting in DNA contamination in the shots. Pfizer and Moderna should have addressed this issue during the manufacturing process by using different enzymes. This shows that assumptions cannot be made when working with new, unnatural products. The DNA used to manufacture the modified RNA was not properly removed, leading to multiple scary aspects of contamination.

A lab owner who previously worked at Monsanto tested five childhood vaccines for glyphosate. All five vaccines tested positive for glyphosate. This is considered statistically significant because when 20 Pediasure feeding tube liquid samples were tested for glyphosate, only six came back positive. The levels for the MMR vaccine were 25 times higher than the other vaccines. This is believed to be because the MMR vaccine is a live virus vaccine, and 25% of it must be gelatin to stabilize the live virus. The gelatin comes from pigs fed GMO grains containing glyphosate.

We analyzed various vaccine lots donated by Dr. Martin Monteverde at Etech in Cordoba. The study was conducted without conflict of interest, as the researcher was unaware of the samples' identities until recently. This secrecy arose because many facilities refused to participate once they learned the samples were COVID vaccines, highlighting a taboo subject. We can no longer remain silent about this serious issue. Our findings indicate that the global population, particularly those vaccinated, has been affected. We analyzed multiple batches from different brands, including AstraZeneca, Sputnik, Sinopharm, Pfizer, and Moderna. The researcher initially aimed to quantify 24 previously detected elements globally, but the analysis revealed much more complexity.